OOIR: Observatory of International Research

Papers

(The median citation count of Annual Review of Pharmacology and Toxicology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
How Biologics Have Changed the Drug Discovery Landscape	118
Pharmacology of Intestinal Inflammation and Repair	112
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease	106
Age-Related Perioperative Neurocognitive Disorders: Experimental Models and Druggable Targets	98
Measuring Pharmacogene Variant Function at Scale Using Multiplexed Assays	90
Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology	78
Evolving Approaches for Pharmacological Therapy of Obesity	70
Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities	66
Introduction to the Theme “Pharmacological Individuality: New Insights and Strategies for Personalized and Precise Drug Treatment”	65
Mitogen-Activated Protein Kinase Phosphatases: No Longer Undruggable?	64
E-Cigarette Toxicology	63
Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development	62
Introduction to the Theme “Development of New Drugs: Moving from the Bench to Bedside and Improved Patient Care”	58
	57
The Gut Microbiome, Metformin, and Aging	55
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer	54
Inhibitors of Intracellular RyR2 Calcium Release Channels as Therapeutic Agents in Arrhythmogenic Heart Diseases	51
Hear and Now: Ongoing Clinical Trials to Prevent Drug-Induced Hearing Loss	51
Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges	50
Endocannabinoid-Based Therapies	50
GPCR Biosensors to Study Conformational Dynamics and Signaling in Drug Discovery	47
G Protein–Coupled Receptor Heteromers in Brain: Functional and Therapeutic Importance in Neuropsychiatric Disorders	47
OAT, OATP, and MRP Drug Transporters and the Remote Sensing and Signaling Theory	46
Health Digital Twins in Life Science and Health Care Innovation	46
Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon	45

Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies	42
Synthetic Cannabinoids: A Pharmacological and Toxicological Overview	41
Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation	40
Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment	39
Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments	37
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy	36
Translational In Vivo Assays in Behavioral Biology	33
Pharmacogenetics of Antiplatelet Therapy	33
Prospects for Disease Slowing in Parkinson Disease	32
Oxidative Stress and Metabolism: A Mechanistic Insight for Glyphosate Toxicology	31
Drug Target Identification in Tissues by Thermal Proteome Profiling	31
G Protein–Coupled Estrogen Receptor GPER: Molecular Pharmacology and Therapeutic Applications	30
What Structural Biology Tells Us About the Mode of Action and Detection of Toxicants	29
Resolution Pharmacology: Focus on Pro-Resolving Annexin A1 and Lipid Mediators for Therapeutic Innovation in Inflammation	29
Targeting Efferocytosis in Inflammaging	27
Pharmacological Induction of Granulocyte Cell Death as Therapeutic Strategy	27
Progress and Challenges in the Field of Snakebite Envenoming Therapeutics	27
Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health	27
Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders	26
Pharmacology of TRPC Channels and Its Potential in Cardiovascular and Metabolic Medicine	24
Lysosomal Ion Channels: What Are They Good For and Are They Druggable Targets?	23
Alcohol Use Disorder Treatment: Problems and Solutions	21
Treating Sickle Cell Disease: Gene Therapy Approaches	20
Advancements in Assays for Micro- and Nanoplastic Detection: Paving the Way for Biomonitoring and Exposomics Studies	20
Harnessing the Power of Electronic Health Records and Genomics for Drug Discovery	20
Brain-Protective Mechanisms of Transcription Factor NRF2: Toward a Common Strategy for Neurodegenerative Diseases	19
Antiepileptic Drugs as Potential Dementia Prophylactics Following Traumatic Brain Injury	18
Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response	17
Deciphering Drug Targets and Actions with Single-Cell and Spatial Resolution	17
Precision Medicine Approaches for Infantile-Onset Developmental and Epileptic Encephalopathies	16
G Protein–Coupled Receptor Signaling: New Insights Define Cellular Nanodomains	16
Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure	16
Genetically Enriched Clinical Trials for Precision Development of Noncancer Therapeutics: A Scoping Review	16
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation	16
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics	15
Aryl Hydrocarbon Receptor and Its Diverse Ligands and Functions: An Exposome Receptor	15
CaMKII as a Therapeutic Target in Cardiovascular Disease	14
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance	14
Endocrine-Disrupting Chemicals and Child Health	14